Discovery of tofogliflozin, a novel C-arylglucoside with an O-spiroketal ring system, as a highly selective sodium glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes

Journal of Medicinal Chemistry

Volumn 55, Issue 17, 2012, Pages 7828-7840

  Ohtake, Yoshihito ^a   Sato, Tsutomu ^a   Kobayashi, Takamitsu ^a   Nishimoto, Masahiro ^a   Taka, Naoki ^a   Takano, Koji ^a   Yamamoto, Keisuke ^a   Ohmori, Masayuki ^a   Yamaguchi, Marina ^a   Takami, Kyoko ^a   Yeu, Sang Yong ^b   Ahn, Koo Hyeon ^c   Matsuoka, Hiroharu ^a   Morikawa, Kazumi ^a   Suzuki, Masayuki ^a   Hagita, Hitoshi ^b   Ozawa, Kazuharu ^a   Yamaguchi, Koji ^a   Kato, Motohiro ^a   Ikeda, Sachiya ^a  

^a CHUGAI PHARMACEUTICAL CO LTD   (Japan)

^b Chugai Research Institute for Medical Science Inc   (Japan)

^c Sungkyunkwan University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

3',4',5' TRI(ACETOXY) 6' ACETOXYMETHYL 5 CHLORO 6 (4 ETHYLPHENYL)METHYL]3',4',5',6' TETRAHYDRO 3H SPIRO[2 BENZOFURAN 1,2' PYRAN] 3'4'5' TRIOL; 3',4',5' TRIHYDROXY6' [(HYDROXYMETHYL)] 3',4',5',6' TETRAHYDRO 3H SPIRO[2 BENZOFURAN 1,2' PYRAN] 6 YL)METHYL)BENZONITRILE; 6 (HYDROXYMETHYL) 6 [(4 ISOPROPYLPHENYL)] 3',4',5',6' TETRAHYDRO 3H SPIRO[2 BENZOFURAN 1,2' PYRAN] 3'4'5' TRIOL; 6 [(4 CHLOROPHENYL)METHYL] 6 [[(HYDROXYMETHYL) 6 (4 HYDROXYMETHYL)]] 3',4',5',6' TETRAHYDRO 3H SPIRO[2 BENZOFURAN 1,2' PYRAN] 3'4'5' TRIOL; 6 [(4 CYCLOPROPYLPHENYL)METHYL] 6' (HYDROXYMETHYL) 3',4',5',6' TETRAHYDRO 3H SPIRO[2 BENZOFURAN 1,2' PYRAN] 3'4'5' TRIOL; 6 [(4 ETHOXYPHENYL)METHYL] 6 [(HYDROXYMETHYL) 6 (4 ISOPROPYLPHENYL)] 3',4',5',6' TETRAHYDRO 3H SPIRO[2 BENZOFURAN 1,2' PYRAN] 3'4'5' TRIOL; 6 [(4 FLUOROPHENYL)METHYL] 6 [[(HYDROXYMETHYL)]] 3',4',5',6' TETRAHYDRO 3H SPIRO[2 BENZOFURAN 1,2' PYRAN] 3'4'5' TRIOL; 6 [(4 HYDROXYPHENYL)METHYL] 6' (HYDROXYMETHYL) 3?,4?,5?,6?-TETRAHYDRO 3H SPIRO[2 BENZOFURAN 1,2 PYRAN] 3',4',5' TRIOL; 6 [[(4ETHYLPHENYL)METHYL] 6'(4 HYDROXYMETHYL)] 3',4',5',6' TETRAHYDRO 3H SPIRO[2 BENZOFURAN 1,2' PYRAN] 3'4'5' TRIOL; 6 [[(HYDROXYMETHYL) 6 (4 ISOPROPYLPHENYL)]] 3',4',5',6' TETRAHYDRO 3H SPIRO[2 BENZOFURAN 1,2' PYRAN] 3'4'5' TRIOL; 6 [[(HYDROXYMETHYL) 6 (4 METHOXYPHENYL)METHYL]] 3',4',5',6' TETRAHYDRO 3H SPIRO[2 BENZOFURAN 1,2' PYRAN] 3'4'5' TRIOL; 6' (HYDROXYMETHYL) 6 [(4 (METHYLTHIO)PHENYL]METHYL] 3',4',5',6' TETRAHYDRO 3H SPIRO[2 BENZOFURAN 1,2' PYRAN] 3'4'5' TRIOL; 6' [(HYDROXYMETHYL) 6 [(4 (TRIFLUOROMETHOXY)PHENYL]METHYL]3',4',5',6' TETRAHYDRO 3H SPIRO[2 BENZOFURAN 1,2' PYRAN] 3'4'5' TRIOL; 6' [[(HYDROXYMETHYL) 6 (4 TRIFLUOROXYMETHYL)]] 3',4',5',6' TETRAHYDRO 3H SPIRO[2 BENZOFURAN 1,2' PYRAN] 3'4'5' TRIOL; CANAGLIFLOZIN; DAPAGLIFLOZIN; ENZYME INHIBITOR; GLUCOSIDE; MOLECULAR SCAFFOLD; PHLORIZIN; REMOGLIFLOZIN ETABONATE; SERGLIFLOZIN ETABONATE; SODIUM GLUCOSE COTRANSPORTER 2; TOFOGLIFLOZIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMPUTER MODEL; CONTROLLED STUDY; DATA BASE; DRUG STRUCTURE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUCLEOTIDE SEQUENCE; PHARMACOPHORE; RING OPENING;

ANIMALS; BENZHYDRYL COMPOUNDS; DIABETES MELLITUS, TYPE 2; GLUCOSIDES; HUMANS; MACACA FASCICULARIS; MAGNETIC RESONANCE SPECTROSCOPY; MICE; MICE, INBRED ICR; MODELS, MOLECULAR; SODIUM-GLUCOSE TRANSPORTER 2; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION;

EID: 84866336965     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm300884k     Document Type: Article

References (68)

1. Diabetes: Fact Sheet No. 312 World Health Organization: Geneva, 2011; http://www.who.int/mediacentre/factsheets/fs312/en/.
2. Stratton, I. M.; Asler, A. I.; Neil, H. A.; Matthews, D. R.; Manley, S. E.; Cull, C. A.; Hadden, D.; Turner, R. C.; Holman, R. R. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study Br. Med. J. 2000, 321, 405-412 (Pubitemid 30609442)
3. Fowler, M. J. Microvascular and Macrovascular Complications of Diabetes Clin. Diabetes 2008, 26, 77-82 (Pubitemid 351556223)
4. Chao, E. C.; Henry, R. R. SGLT2 inhibition - A novel strategy for diabetes treatment Nature Rev. Drug Discovery 2010, 9, 551-559
5. Nomura, S. Renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for new anti-diabetic agent Curr. Top. Med. Chem. 2010, 10, 411-418
6. +/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for d -glucose J. Clin. Invest. 1994, 93, 397-404
7. Kipnes, M. Dapagliflozin: an emerging treatment option in type 2 diabetes Expert Opin. Invest. Drugs 2009, 18, 335-348
8. Komoroski, B.; Vachharajani, N.; Feng, Y.; Li, L.; Kornhauser, D.; Pfister, M. Dapgliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus Clin. Pharmacol. Ther. 2009, 85, 513-519
9. White, J. R., Jr. Apple Trees to Sodium Glucose Co-Transporter Inhibitors: A Review of SGLT2 Inhibition Clin. Diabetes 2010, 28, 5-10
10. Muhammad, A. A.; Norton, L.; DeFronzo, R. A. Efficacy and Safety of SGLT2 Inhibitors in the Treatment of Type 2 Diabetes Mellitus Curr. Diabetes Rep. 2012, 12, 230-238
11. Kleta, R.; Stuart, C.; Gill, F. A.; Gahl, W. A. Renal glucosuria due to SGLT2 mutations Mol. Genet. Metab. 2004, 82, 56-58 (Pubitemid 38521129)
12. Magen, D.; Sprecher, E.; Zelikovic, I.; Skorecki, K. A novel missense mutation in SLC5A2 encoding SGLT2 underlies autosomal-recessive renal glucosuria and aminoaciduria Kidney Int. 2005, 67, 34-41 (Pubitemid 40019223)
13. Santer, R.; Kinner, M.; Lassen, C. L.; Schneppenheim, R.; Eggert, P.; Bald, M.; Brodehl, J.; Daschner, M.; Ehrich, J. H.; Kemper, M.; Li, V. S.; Neuhaus, T.; Skovby, F.; Swift, P. G.; Schaub, J.; Klaerke, D. Molecular analysis of the SGLT2 gene in patient with renal glucosuria J. Am. Soc. Nephrol. 2003, 14, 2873-2882 (Pubitemid 37305650)
14. Wright, E. M.; Loo, D. D.; Hirayama, B. A. Biology of human sodium glucose transporters Physiol. Rev. 2011, 91, 733-794
15. +-glucose cotransporters Am. J. Physiol. Renal Physiol. 2001, 280, 10-18
16. Wright, E. M.; Turk, E.; Martin, M. G. Molecular basis for glucose-galactose malabsorption Cell. Biochem. Biophys. 2002, 36, 115-121 (Pubitemid 41270716)
17. +/glucose cotransporter1 (SGLT1) J. Cell Biochem. 2003, 90, 339-346 (Pubitemid 37222202)
18. Banerjee, S. K.; McGaffin, K. R.; Pastor-Soler, N. M. Ahmad, F. SGLT1 is a novel cardiac glucose transporter that is perturbed in disease states Cardiovasc. Res. 2009, 84, 111-118
19. Banerjee, S. K.; Wang, D. W.; Alzamora, R.; Huang, X. N.; Pastor-Soler, N. M.; Hallows, K. R.; McGaffin, K. R.; Ahmad, F. SGLT1, a Novel Cardiac Glucose Transporter, Mediates Increased Glucose Uptake in PRKAG2 Cardiomyopathy J. Mol. Cell Cardiol. 2010, 49, 683-692
20. List, J. F.; Whaley, J. M. Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans Kidney Int. 2011, 79, 20-27
21. Ehrenkraz, J. R. L.; Lewis, N. G.; Kahn, C. R.; Roth, J. Phlorizin: a review Diabetes/Metab. Res. Rev. 2005, 21, 31-38
22. +-glucose co-transporter inhibitor. PCT Int. Appl. WO2004080990, 2004
23. Chem. Abstr. 2004, 141, 296242.
24. Goodwin, N. C.; Harrison, B. A.; Iimura, S.; Mabon, R.; Song, Q.; Wu, W.; Yan, J.; Zhang, H.; Zhao, M. M. Preparation of glycosyl sulfoxides as potential antidiabetic sodium glucose co-transporter 2 inhibitors. PCT Int. Appl. WO2009014970, 2009
25. Chem. Abstr. 2009, 150, 144780.
26. Goodwin, N. C.; Mabon, R.; Harrison, B. A.; Shadoan, M. K.; Almstead, Z. Y.; Xie, Y.; Healy, J.; Buhring, L. M.; DaCosta, C. M.; Bardenhagen, J.; Mseeh, F.; Liu, Q.; Nouraldeen, A.; Wilson, A. G. E.; Kimball, S. D.; Powell, D. R.; Rawlins, D. B. Novel l -xylose derivatives as selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes J. Med. Chem. 2009, 52, 6201-6204
27. Kakinuma, H.; Oi, T.; Hashimoto-Tsuchiya, Y.; Arai, M.; Kawakita, Y.; Fukasawa, Y.; Iida, I.; Hagima, N.; Takeuchi, H.; Chino, Y.; Asami, J.; Okumura-Kitajima, L.; Io, F.; Yamamoto, D.; Miyata, N.; Takahashi, T.; Uchida, S.; Yamamoto, K. (1 S)-1,5-Anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4- methylphenyl]-1-thio- d -glucitol (TS-071) is a potent, selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for type 2 diabetes treatment J. Med. Chem. 2010, 53, 3247-3261
28. Mascitti, V.; Collman, B. M. Preparation of dioxa-bicyclo[3.2.1]octane-2, 3,4-triol derivatives as antidiabetic agents. PCT Int. Appl. WO2010023594, 2010
29. Chem. Abstr. 2010, 152, 311862.
30. Mascitti, V.; Maurer, R. S.; Robinson, R. P.; Bian, J.; Boustany-Kari, C. M.; Brandt, T.; Collman, B. M.; Kalgutkar, A. S.; Klenotic, M. K.; Leininger, M. T.; Lowe, A.; Maguire, R. J.; Masterson, V. M.; Miao, Z.; Mukaiyama, E.; Patel, J. D.; Pettersen, J. C.; Préville, C.; Samas, B.; Li, S.; Sobol, Z.; Steppan, C. M.; Stevens, B. D.; Thuma, B. A.; Tugnait, M.; Zeng, D.; Zhu, T. Discovery of a clinical candidate from the structurally unique dioxa-bicyclo[3.2.1]octane class of sodium-dependent glucose cotransporter 2 inhibitors J. Med. Chem. 2011, 54, 2952-2960
31. +-glucose cotransporters, may provide a novel approach to treating diabetes Diabetes 1999, 48, 1794
32. +-Glucose Cotransporter (SGLT) Inhibitors as Antidiabetic Agents. 4. Synthesis and Pharmacological Properties of 4′-Dehydroxyphlorizin Derivatives Substituted on the B Ring J. Med. Chem. 1999, 42, 5311-5324 (Pubitemid 30036767)
33. Fujikura, H.; Fushimi, N.; Nishimura, T.; Tatani, K.; Isaji, M. Preparation of glucopyranosyloxybenzylbenzene derivatives as inhibitors of human SGLT2 (sodium-dependent glucose-transporter 2) activity and medicinal compositions containing the same. U.S. Patent US6,872,706, 2005
34. Chem. Abstr. 2002, 136, 295018.
35. Katsuno, K.; Fujimori, Y.; Takemura, Y.; Hiratochi, M.; Itoh, F.; Komatsu, Y.; Fujikura, H.; Isaji, M. Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level J. Pharmacol. Exp. Ther. 2007, 320, 323-330 (Pubitemid 46025747)
36. Fujikura, H.; Fushimi, N.; Nishimura, T.; Nakabayashi, T.; Isaji, M. Preparation of glucopyranosyloxypyrazole derivatives as inhibitors of human SGLT2 (sodium-dependent glucose-transporter 2) activity and use thereof in medicines. PCT Int. Appl. WO 2002053573, 2002
37. Chem. Abstr. 2002, 137, 93946.
38. Fujimori, Y.; Katsuno, K.; Nakashima, I.; Ishikawa-Takemura, Y.; Fujikura, H.; Isaji, M. Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models J. Pharmacol. Exp. Ther. 2008, 327, 268-276
39. Meng, W.; Ellsworth, B. A.; Nirschl, A. A.; McCann, P. J.; Patel, M.; Girotra, R. N.; Wu, G.; Sher, P. M.; Morrison, E. P.; Biller, S. A.; Zahlar, R.; Deshpande, P. P.; Pullockaran, A.; Hagan, D. L.; Morgan, N.; Taylor, J. R.; Obermeier, M. T.; Humphreys, W. G.; Khanna, A.; Discenza, L.; Robertson, J. G.; Wang, A.; Han, S.; Wetterau, J. R.; Janovitz, E. B.; Flint, O. P.; Whaley, J. M.; Washburn, W. N. Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes J. Med. Chem. 2008, 51, 1145-1149 (Pubitemid 351480378)
40. Nomura, S.; Sakamaki, S.; Hongu, M.; Kawanishi, E.; Koga, Y.; Sakamoto, T.; Yamamoto, Y.; Ueta, K.; Kimata, H.; Nakayama, K.; Tsuda-Tsukimoto, M. Discovery of canagliflozin, a novel C -glucoside with thiophene ring, as sodium-dependent glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes mellitus J. Med. Chem. 2010, 53, 6355-6360
41. Nomura, S.; Kawanishi, E.; Ueta, K. Preparation of glycosides as antidiabetic agents and having inhibitory activity against sodium-dependant transporter. PCT Int. Appl. WO2005012326, 2005
42. Chem. Abstr. 2005, 142, 219491.
43. Eckhardt, M.; Eickelmann, P.; Himmelsbach, F.; Barsoumian, E. L.; Thomas, L. Preparation of glucopyranosyl-substituted phenyl derivatives antidiabetic agents and SGLT2 inhibitors. U.S. Patent US7,579,449, 2009
44. Chem. Abstr. 2005, 143, 286629.
45. Chugai Pharmaceutical Co. Ltd. was issued a patent on the O -spiroketal C -arylglucosides: Kobayashi, T.; Sato, T.; Nishimoto, M. Spiroketal derivative and use thereof as diabetic medicine. U.S. Patent US7,767,651, 2010
46. Chem. Abstr. 2006, 145, 189115.
47. Sato, T.; Kobayashi, T.; Nishimoto, M.; Taka, N.; Ohtake, Y.; Takano, K.; Yamamoto, K.; Ohmori, M.; Yamaguchi, M.; Takami, K.; Yeu, S.-Y.; Ahn, K.-H.; Matsuoka, H.; Suzuki, M.; Hagita, H.; Ozawa, K.; Yamaguchi, K.; Kato, M.; Ikeda, S. Discovery of O -spiroketal C -arylglucosides as novel and selective sodium-dependent glucose cotransporter s (SGLT2) inhibitor for the treatment of type 2 diabetes. Division of Medicinal Chemistry. Scientific Abstracts for the 240th National ACS Meeting and Exposition, Boston, MA, Aug 22-26, 2010, MEDI-202.
48. Xu, B; Lv, B; Feng, Y; Xu, G; Du, J; Welihinda, A; Sheng, Z; Seed, B; Chen, Y. O -Spiro C -aryl glucosides as novel sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors Bioorg. Med. Chem. Lett. 2009, 19, 5632-5635
49. Lv, B; Xu, B; Feng, Y; Peng, K; Xu, G; Du, J; Zhang, L; Zhang, W; Zhang, T; Zhu, L; Ding, H; Sheng, Z; Welihinda, A; Seed, B; Chen, Y. Exploration of O -spiroketal C -arylglucosides as novel and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors Bioorg. Med. Chem. Lett. 2009, 19, 6877-6881
50. Suzuki, M.; Honda, K.; Fukazawa, M.; Ozawa, K.; Hagita, H.; Kawai, T.; Takeda, M.; Yata, T.; Kawai, M.; Fukuzawa, T.; Kobayashi, T.; Sato, T.; Kawabe, Y.; Ikeda, S. Tofogliflozin, a potent and highly specific sodium/glucose cotransporter 2 inhibitor, improves glycemic control in diabetic rats and mice J. Pharmacol. Exp. Ther. 2012, 341, 692-701
51. +/sugar symport Science 2008, 321 (5890) 810-814
52. Wright, E. M.; Loo, D. D. F.; Hirayama, B. A. Biology of Human Sodium Glucose Transporters Physiol. Rev. 2011, 91, 733-794
53. +-glucose cotransporter inhibitors. PCT Int. Appl. WO2006011469, 2006
54. Chem. Abstr. 2006, 144, 192446.
55. Ohtake, Y.; Sato, T.; Matsuoka, H.; Nishimoto, M.; Taka, N.; Takano, K.; Yamamoto, K.; Ohmori, M.; Higuchi, T.; Murakata, M.; Kobayashi, T.; Morikawa, K.; Shimma, N.; Suzuki, M.; Hagita, H.; Ozawa, K.; Yamaguchi, K.; Kato, M.; Ikeda, S. 5a-Carba-β- d -glucopyranose derivatives as novel sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes Bioorg. Med. Chem. 2011, 19, 5334-5341
56. Ohtake, Y.; Sato, T.; Kobayashi, T.; Matsuoka, H.; Nishimoto, M.; Taka, N.; Takano, K.; Yamamoto, K.; Ohmori, M.; Higuchi, T.; Murakata, M.; Morikawa, K.; Shimma, N.; Suzuki, M.; Hagita, H.; Ozawa, K.; Yamaguchi, K.; Kato, M.; Ikeda, S. C -Aryl 5a-carba-β- d -glucopyranosides as novel sodium glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes Bioorg. Med. Chem. 2012, 20, 4117-4127
57. Matsuoka, M.; Sato, T.; Nishimoto, M.; Kato, Y.; Sakaitani, M.; Lee, S.-H. Novel glucitol derivative, prodrug thereof and salt thereof, and therapeutic agent containing the same for diabetes. PCT Int. Appl. WO2006011502, 2006
58. Chem. Abstr. 2006, 144, 171191.
59. Molecular Operating Environment v2010.10; Chemical Computing Group, Inc.: Montreal, Quebec, 2010.
60. CSD: version 2.25; The Cambridge Crystallographic Data Centre: 12 Union Road, Cambridge, CB2 1EZ, UK, November, 2004.
61. Traxler, P.; Fritz, H.; Fuhrer, H.; Richter, W. J. Papulacandins, a new family of antibiotics with antifungal activity. Structures of papulacandins A, B, C and D J. Antibiot. (Tokyo) 1980, 33, 967-978 (Pubitemid 11192530)
62. Czernecki, S.; Perlat, M. C. C -Glycosides. 9. Stereospecific synthesis of C -glycosidic spiroketal of the papulacandins J. Org. Chem. 1991, 56, 6289-6292
63. Nobre, S. M.; Monteiro, A. L. Synthesis of diarylmethane derivatives from Pd-catalyzed cross-coupling reactions of benzylic halides with arylboronic acids Tetrahedron Lett. 2004, 45, 8225-8228 (Pubitemid 39311874)
64. Gelman, D.; Buchwald, S. L. Efficient palladium-catalyzed coupling of aryl chlorides and tosylates with terminal alkynes: use of a copper cocatalyst inhibits the reaction Angew. Chem., Int. Ed. 2003, 42, 5993-5996 (Pubitemid 38063504)
65. Kataoka, N.; Shelby, Q.; Stambuli, J. P.; Hartwig, J. F. Air stable, sterically hindered ferrocenyl dialkylphosphines for palladium-catalyzed C-C, C-N, and C-O bond-forming cross-couplings J. Org. Chem. 2002, 67, 5553-5566 (Pubitemid 34851595)
66. Sekiguchi, N.; Higashida, A.; Kato, M.; Nabuchi, Y.; Mitsui, T.; Takanashi, K.; Aso, Y.; Ishigai, M. Prediction of drug-drug interactions based on time-dependent inhibition from high throughput screening of cytochrome P450 3A4 inhibition Drug Metab. Pharmacokinet. 2009, 24, 500-510
67. Horton, D.; Priebe, W. Synthetic routes to higher-carbon sugars. Reaction of lactones with 2-lithio-1,3-dithiane Carbohydr. Res. 1981, 94, 27-41
68. Halgren, T. A. Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94 J. Comput. Chem. 1996, 17, 490-519 (Pubitemid 126567067)